- Home
- HOND vs CAPR Comparison
HOND vs CAPR Comparison
Compare HOND & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOND
- CAPR
- Stock Information
- Founded
- HOND 2024
- CAPR 2005
- Country
- HOND United States
- CAPR United States
- Employees
- HOND N/A
- CAPR N/A
- Industry
- HOND
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOND
- CAPR Health Care
- Exchange
- HOND NYSE
- CAPR Nasdaq
- Market Cap
- HOND 287.5M
- CAPR 332.5M
- IPO Year
- HOND 2024
- CAPR N/A
- Fundamental
- Price
- HOND $10.00
- CAPR $17.79
- Analyst Decision
- HOND
- CAPR Strong Buy
- Analyst Count
- HOND 0
- CAPR 7
- Target Price
- HOND N/A
- CAPR $39.29
- AVG Volume (30 Days)
- HOND 1.5K
- CAPR 1.1M
- Earning Date
- HOND 01-01-0001
- CAPR 11-13-2024
- Dividend Yield
- HOND N/A
- CAPR N/A
- EPS Growth
- HOND N/A
- CAPR N/A
- EPS
- HOND N/A
- CAPR N/A
- Revenue
- HOND N/A
- CAPR $23,228,045.00
- Revenue This Year
- HOND N/A
- CAPR N/A
- Revenue Next Year
- HOND N/A
- CAPR $135.53
- P/E Ratio
- HOND N/A
- CAPR N/A
- Revenue Growth
- HOND N/A
- CAPR 65.33
- 52 Week Low
- HOND $9.97
- CAPR $2.90
- 52 Week High
- HOND $11.57
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- HOND N/A
- CAPR 47.77
- Support Level
- HOND N/A
- CAPR $17.21
- Resistance Level
- HOND N/A
- CAPR $19.47
- Average True Range (ATR)
- HOND 0.00
- CAPR 1.64
- MACD
- HOND 0.00
- CAPR -0.38
- Stochastic Oscillator
- HOND 0.00
- CAPR 28.33
About HOND HCM II ACQUISITION CORP
HCM II Acquisition Corp is a blank check company.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.